Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
What will members gain?
eBook

AHA Scientific Sessions
10-12 November, 2018

AHA2018

CHECK BACK FOR REPORTAGE FROM THIS YEAR'S SESSIONS


Most viewed
Most viewed

Lipoprotein(a) – does it matter when LDL cholesterol is low?

Lipoprotein(a) is now recognised as an independent risk factor for cardiovascular disease.

But is it also relevant to consider lipoprotein(a) when LDL cholesterol is low?

Prof. Anthony S Wierzbicki, Guy’s and St Thomas’ Hospitals, London, UK discusses the evidence.

Read the report

Hot Topics

Guidance needed on LDL lowering in very high-risk patients

Do high and very high-risk patients at guideline-recommended goal gain more benefit from further lowering LDL cholesterol levels?

PCSK9 Forum Editor Professor John Chapman (UPMC-Sorbonne, Director Emeritus, INSERM, Paris, France), discusses.

 

Read the report

Video: Impetus to change LDL-C goal from FOURIER
Watch the video

 

From the Editors

Is LDL-apheresis still needed in the PCSK9 era?

With the advent of PCSK9 monoclonal antibodies, reduction in LDL-cholesterol levels by up to 80-90% is now possible, when combined with statins and ezetimibe. What role does LDL-apheresis have in this new era?

Dr Peter Lansberg, University Medical Center Groningen, The Netherlands, discusses.

Read the report

Watch the video
 

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology